Should we be morbid about comorbidities in the rheumatic diseases?

Rheumatology (United Kingdom)

Volumn 52, Issue 1, 2013, Pages 1-2

  Elewaut, Dirk ^a   Goodson, Nicola ^b   Fleischmann, Roy ^c,d  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d METROPLEX CLINICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; IMMUNOMODULATING AGENT;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMORBIDITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DISEASE SURVEILLANCE; EDITORIAL; GOUT; HODGKIN DISEASE; HUMAN; INFECTION; LOWER RESPIRATORY TRACT INFECTION; LUNG CANCER; MEDICAL DECISION MAKING; METABOLIC SYNDROME X; NONHODGKIN LYMPHOMA; OSTEOARTHRITIS; PRIORITY JOURNAL; RHEUMATIC DISEASE; SLEEP DISORDERED BREATHING; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; URIC ACID BLOOD LEVEL; VASCULITIS;

COMORBIDITY; HUMANS; RHEUMATIC DISEASES; RISK FACTORS;

EID: 84871159343     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes361     Document Type: Editorial

References (10)

1. Robinson PC, Merriman TR, Herbison P, Highton J. Hospital admissions associated with gout and their comorbidities in New Zealand and England 1998-2009. Rheumatology 2013;52:118-26.
2. Kuo C-F, Yu K-H, See L-C et al. Risk of myocardial infarction among patients with gout: a nationwide population-based study. Rheumatology 2013;52:111-17.
3. Taylor-Gjevre RM, Nair BV, Gjevre JA. Obstructive sleep apnoea in relation to rheumatic disease. Rheumatology 2013;52:15-21.
4. Stamp LK, Chapman PT. Gout and its comorbidities: implications for therapy. Rheumatology 2013;52:34-44.
5. Thornley S, Marshall RJ, Jackson R et al. Is serum urate causally associated with incident cardiovascular disease? Rheumatology 2013;52:135-42.
6. Peterman Smits DR, Wilde B, Kianersi Adegani M et al. Metabolic syndrome in ANCA-associated vasculitis. Rheumatology 2013;52:197-203.
7. Mathieu S, Pereira B, Couderc M et al. No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor-alpha blockade treatment for 6 and 12 months. Rheumatology 2013;52: 204-9.
8. Avina-Zubieta JA, Abrahamowicz M, De Vera MA et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology 2013;52:68-75.
9. Mercer LK, Davies R, Galloway JB et al. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology 2013;52:91-8.
10. Moore OA, Goh N, Corte T et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology 2013;52:155-60.